logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Surufatinib CAS 1308672-74-3

Surufatinib CAS 1308672-74-3

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 1308672-74-3

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
1308672-74-3
Appearance::
Off-white To White Solid Powder
Molecular Formula::
C24H28N6O3S
Molecular Weight::
480.58300
EINECS NO::
NA
MDL NO::
NA
CAS NO::
1308672-74-3
Appearance::
Off-white To White Solid Powder
Molecular Formula::
C24H28N6O3S
Molecular Weight::
480.58300
EINECS NO::
NA
MDL NO::
NA
Surufatinib CAS 1308672-74-3

Product Description:

Product Name: surufatinib CAS NO: 1308672-74-3

 

 

 

Synonyms:

KDR-IN-1;

EOS-61498;

HMPL012;

 

 

 

Chemical & Physical Properties:

Appearance: Off-white to white solid powder

Assay :≥98.0%

Density: 1.332±0.06 g/cm3 (Predicted)

Boiling point/range 712.9±70.0℃ at 760 mmHg

Flash point 385.0±35.7℃

Storage Condition: stored at 0-4℃ for a short period of time, a few days to a few months. The long term can be stored at -20℃ for three years. Store in a cool and dry place

Solubility: Soluble in DMSO

PKa: 5.22±0.40 (Predicted)

 

 

 

Safety Information:

Signal word: Danger

Hazard statements: H315/317/318/334/335/341/361/370/413

Incompatible materials: Strong acids/alkalis, strong oxidising/reducing agents

Hazardous decomposition products: Under fire conditions, may decompose and emit toxic fumes

 

 

 

Sulfatinib (HMPL-012, Sufatinib, Surfatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1, VEGFR2, VEGFR3, FGFR1 and CSF1R with IC50 of 2 nM, 24 nM, 1 nM, 15 nM and 4 nM, respectively. Sulfatinib shows encouraging antitumor activity and manageable toxicities in patients with advanced NETs.

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.